Here's Why Novo Nordisk A/S Gained 12% in August
Shares of Danish pharma giant Novo Nordisk A/S (NYSE: NVO) rose 11.7% in August, according to data from S&P Global Market Intelligence. Investors were relieved to see that the sales stall the company had warned about last summer never materialized, and pleased to see hints of growth ahead.
Novo Nordisk shocked the market in August 2016 with a depressing outlook for its pricey diabetes treatments. Last month, the stock surged when the company reported an 8% operating profit increase for the first half of the year. The company also nudged its total sales forecast for the year upward, from a range of 0% to 3% growth to between 1% and 3% growth, despite continued pressure from U.S. end payers.
Image source: Getty Images.
Source: Fool.com
Eli Lilly Corp. Stock
€867.80
2.200%
The stock is an absolute favorite of our community with 68 Buy predictions and no Sell predictions.
With a target price of 883 € there is a slightly positive potential of 1.75% for Eli Lilly Corp. compared to the current price of 867.8 €.
